Prognostic Impact of Tumor-Infiltrating Immune Cells on Efficacy of Neoadjuvant Chemotherapy in Patients with Advanced or Metastatic Ovarian Cancer: A Retrospective Study

17 July 2024 : Clinical Research

Qunxian Rao^1BCE, Miaoling Huang^1B, Meimei Guan^1C, Changhao Liu^1D, Lijuan Wang^1D, Zhongqiu Lin^1A*, Qing Chen^1A

DOI: 10.12659/MSM.943170

Med Sci Monit 2024; 30:e943170

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Clinicopathological characteristics of patients.

Characteristic	Number (%)

Median	57.8
Range	52–64
FIGO stage
IIIB	2 (6.5)
IIIC	21 (67.7)
IV	8 (25.8)

High-grade	30 (96.8)
Low-grade	1 (3.2)

Benefit	24 (77.4)
Part benefit	6 (19.4)
No benefit	1 (3.2)

With	5 (16.1)
Without	26 (83.9)

With	9 (29.0)
Without	22 (71.0)

T+cisplatin	3 (9.6)
T+carboplatin	14 (45.2)
T+cisplatin following T+carboplatin	14 (45.2)

1	1 (3.2)
3	26 (81.0)
4	1 (3.2)
5	1 (3.2)
7	1 (3.2)
10	1 (3.2)

With	11 (35.5)
Without	20 (64.5)
FIGO – International Federation of Gynecology and Obstetrics; NACT – neoadjuvant chemotherapy; T – docetaxel/albumin-bound paclitaxel/paclitaxel; G-CSF – the use of granulocyte-colony stimulating factor agents during the courses of NACT.

Back to the Article